Log in

NYSE:NGM - NGM Biopharmaceuticals Stock Price, Forecast & News

-0.05 (-0.31 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
Now: $16.19
50-Day Range
MA: $17.41
52-Week Range
Now: $16.19
Volume73,116 shs
Average Volume163,315 shs
Market Capitalization$1.08 billion
P/E RatioN/A
Dividend YieldN/A
NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity. Its products under development also comprise NGM120, an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in preclinical studies to decrease levels of a protein implicated in the dry form of age-related macular degeneration. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp., MedImmune Limited, and JDRF International. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Industry, Sector and Symbol

Industry N/A



Sales & Book Value

Annual SalesN/A



Market Cap$1.08 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableNot Optionable

Receive NGM News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM and its competitors with MarketBeat's FREE daily newsletter.

NGM Biopharmaceuticals (NYSE:NGM) Frequently Asked Questions

What is NGM Biopharmaceuticals' stock symbol?

NGM Biopharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGM."

How were NGM Biopharmaceuticals' earnings last quarter?

NGM Biopharmaceuticals (NYSE:NGM) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.17) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.11. The firm earned $21.57 million during the quarter, compared to analysts' expectations of $17.50 million. View NGM Biopharmaceuticals' Earnings History.

When is NGM Biopharmaceuticals' next earnings date?

NGM Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for NGM Biopharmaceuticals.

What price target have analysts set for NGM?

5 analysts have issued 1-year target prices for NGM Biopharmaceuticals' shares. Their forecasts range from $22.00 to $31.00. On average, they expect NGM Biopharmaceuticals' share price to reach $25.60 in the next twelve months. This suggests a possible upside of 58.1% from the stock's current price. View Analyst Price Targets for NGM Biopharmaceuticals.

What is the consensus analysts' recommendation for NGM Biopharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NGM Biopharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NGM Biopharmaceuticals.

What are Wall Street analysts saying about NGM Biopharmaceuticals stock?

Here are some recent quotes from research analysts about NGM Biopharmaceuticals stock:
  • 1. According to Zacks Investment Research, "NGM Biopharmaceuticals Inc. is focused on developing novel therapeutics for underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's product pipeline consists of NGM282, NGM313, NGM120, NGM217, NGM621, NGM386 and NGM395 which are in clinical stage. NGM Biopharmaceuticals Inc. is based in San Francisco, California. " (2/5/2020)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and $26 target price after NGM reported its 2Q19 financials and business update. We remain positively biased ahead of NGM282’s (aldafermin) Phase 2 cohort 4 interim data expected in 4Q19 (non-invasive biomarkers), but more importantly, aldafermin’s top line results in early 2020 where we believe it has the potential to demonstrate a histological fibrosis benefit in NASH patients in as little as 24 weeks of treatment. The latter remains the key catalyst for the stock, in our view. In the press release, NGM indicated it had completed enrollment for cohort 4 and management also highlighted pipeline progress for some of its earlier stage programs including for NGM621, which is being developed for geographic atrophy, and NGM120 for CACS." (8/14/2019)

Has NGM Biopharmaceuticals been receiving favorable news coverage?

News coverage about NGM stock has trended very positive this week, InfoTrie reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. NGM Biopharmaceuticals earned a news sentiment score of 3.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for NGM Biopharmaceuticals.

What other stocks do shareholders of NGM Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NGM Biopharmaceuticals investors own include Amarin (AMRN), Translate Bio (TBIO), Teva Pharmaceutical Industries (TEVA), Gilead Sciences (GILD), Iovance Biotherapeutics (IOVA), AbbVie (ABBV), Biogen (BIIB), Intercept Pharmaceuticals (ICPT), Pfizer (PFE) and Alexion Pharmaceuticals (ALXN).

Who are NGM Biopharmaceuticals' key executives?

NGM Biopharmaceuticals' management team includes the folowing people:
  • Mr. William J. Rieflin, Exec. Chairman of Directors (Age 59)
  • Dr. David J. Woodhouse, CEO, Acting CFO & Director (Age 48)
  • Dr. Aetna Wun Trombley, Pres & COO (Age 40)
  • Dr. Jin-Long Chen, Founder, Chief Scientific Officer & Director (Age 56)
  • Dr. Hui Tian, Sr. VP of Research

When did NGM Biopharmaceuticals IPO?

(NGM) raised $100 million in an initial public offering (IPO) on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen acted as the underwriters for the IPO.

Who are NGM Biopharmaceuticals' major shareholders?

NGM Biopharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Svennilson Peter (24.64%), State Street Corp (0.57%), Candriam Luxembourg S.C.A. (0.36%), Geode Capital Management LLC (0.28%), Goldman Sachs Group Inc. (0.13%) and Charles Schwab Investment Management Inc. (0.12%). Company insiders that own NGM Biopharmaceuticals stock include David V Goeddel, Group L P Column, Jin-Long Chen, Merck & Co, Inc, Peter Svennilson and Suzanne Sawochka Hooper. View Institutional Ownership Trends for NGM Biopharmaceuticals.

Which institutional investors are selling NGM Biopharmaceuticals stock?

NGM stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc. and Victory Capital Management Inc.. Company insiders that have sold NGM Biopharmaceuticals company stock in the last year include Group L P Column and Jin-Long Chen. View Insider Buying and Selling for NGM Biopharmaceuticals.

Which institutional investors are buying NGM Biopharmaceuticals stock?

NGM stock was purchased by a variety of institutional investors in the last quarter, including Svennilson Peter, State Street Corp, Geode Capital Management LLC, Candriam Luxembourg S.C.A., Oxford Asset Management LLP, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp and Goldman Sachs Group Inc.. Company insiders that have bought NGM Biopharmaceuticals stock in the last two years include David V Goeddel, Group L P Column, Merck & Co, Inc, Peter Svennilson and Suzanne Sawochka Hooper. View Insider Buying and Selling for NGM Biopharmaceuticals.

How do I buy shares of NGM Biopharmaceuticals?

Shares of NGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NGM Biopharmaceuticals' stock price today?

One share of NGM stock can currently be purchased for approximately $16.19.

How big of a company is NGM Biopharmaceuticals?

NGM Biopharmaceuticals has a market capitalization of $1.08 billion. NGM Biopharmaceuticals employs 164 workers across the globe.View Additional Information About NGM Biopharmaceuticals.

What is NGM Biopharmaceuticals' official website?

The official website for NGM Biopharmaceuticals is http://www.ngmbio.com/.

How can I contact NGM Biopharmaceuticals?

The company can be reached via phone at 650-243-5555.

MarketBeat Community Rating for NGM Biopharmaceuticals (NYSE NGM)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  32 (Vote Outperform)
Underperform Votes:  23 (Vote Underperform)
Total Votes:  55
MarketBeat's community ratings are surveys of what our community members think about NGM Biopharmaceuticals and other stocks. Vote "Outperform" if you believe NGM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NGM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Featured Article: 52- Week Highs

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel